Journal of Clinical Oncology
Articles in this Issue
Analysis of citation impact and social media engagement in cancer pain research.
e23120 Background: Cancer-related pain significantly affects patients' quality of life, with up to 66% experiencing severe pain despite advancements in pa...
IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with HER2-positive breast cancer (BC) and other solid tumors: Updates from a phase 1 study.
1029 Background: HER2 has been established as an important therapeutic target for BC. IBI354 consists of trastuzumab (anti-HER2 antibody) conjugated to a...
Clinical large language model to predict loss to follow up for oncology patients discharged to skilled nursing facilities.
e13597 Background: From SEER data, there is evidence that oncology patients who are discharged to a skilled nursing facility are less likely to receive ch...
Exploring treatment adherence and unmet needs of older breast cancer survival in Nigeria.
e13849 Background: Breast cancer is the leading cause of cancer death in Nigeria. Older breast cancer patients often experience additional vulnerabilities...
Unexplored targets in myeloid neoplasms: Investigating potential areas of clinical actionability using a comprehensive genomic database.
e23269 Background: Mutations like EZH2, BRAF, KRAS, EGFR and others have been widely studied in lymphoid and solid malignancies where they are implicated...
Efficacy of CDK4/6 inhibitors post-chemotherapy in HR+ HER2- metastatic breast cancer patients: Real-world study.
e13096 Background: CDK4/6 inhibitors are established first- and second-line treatments for HR+, HER2- metastatic breast cancer, particularly in combinatio...
Phase 1 trial of HCB101, a novel Fc-based anti-SIRPα-CD47 fusion protein, in subjects with advanced cancers.
2584 Background: CD47-targeting agents face challenges, including “on-target, off-tumor” toxicities affecting red blood cells, limited efficacy, and manuf...
Exploring barriers, facilitators and best practices for optimal provider-to-provider communication in hematopoietic cell transplant.
e13550 Background: Despite its importance for care coordination, provider-to-provider communication (P2PC) across a patient’s hematopoietic cell transplan...
Effect of metabolic syndrome on survival among patients with breast or prostate cancer.
e22615 Background: Metabolic syndrome is defined as the presence of at least 3 of the following metabolic conditions: dysg...
Racial disparities in mortality and length of hospital stay following palliative transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Insights from the 2021 National Inpatient Sample (NIS).
e16263 Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, and Transarterial Chemoembolization (TACE) is...
Managing the invisible: Treatment approaches after pathological complete response (pCR) to neoadjuvant chemotherapy in oral cancer.
e18112 Background: Pathological complete response (pCR) following neoadjuvant chemotherapy (NACT) in locally advanced oral squamous cell carcinoma (LA-OSC...
Cerebrospinal fluid derived ctDNA and CTC based molecular analysis highlighting the sampling proximity for clinical significance.
e14012 Background: ctDNA based liquid biopsies have transformed cancer care by enabling the detection of actionable mutations, monitoring progression, the...
Real world evidence of survival in locally advanced esophago-gastric cancers treated with perioperative chemotherapy vs preoperative chemoradiotherapy.
e16162 Background: Upper GI (UGI) adenocarcinoma - esophageal, gastroesophageal junction (GEJ), and gastric - are among the leading causes of cancer death...
Vaccination by homologous antigenic loading with DOC1021 as adjuvant therapy for glioblastoma: Phase I clinical trial results.
2014 Background: Glioblastoma is a devastating tumor for which median overall survival (mOS) remains 14-18 months despite...
Molecular characterization and clinical relevance of metabolic signature subtypes in gastric cancer.
e16040 Background: Metabolic reprogramming dictates the tumor molecular attributes and therapeutic potentials. However, the comprehensive metabolic charac...
First-in-human study of CJRB-101, a live biotherapeutic product in combination with pembrolizumab in selected types of advanced or metastatic cancer.
8547 Background: CJRB-101 is a live biotherapeutic product containing a novel strain belonging in the species Leuconostoc mesenteroides...
Quantitative parameters on whole-body diffusion weighted MRI (WB-DWMRI) and PSMA PET/CT in <sup>177</sup> Lu-PSMA therapy for metastatic prostate cancer (mPC).
e17034 Background: This original study explores the utility of quantitative imaging biomarkers from WB-DWMRI and PSMA-PET/CT in predicting lesion-level re...
Plasma metabolic signatures in epithelial ovarian cancer diagnosis: The application of NextGen Metabolomics in gynecologic oncology.
e17593 Background: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. The lack of reliable diagnostic tests for early detection ha...
Fragmentation of cell-free DNA (cfDNA) in locally advanced rectal cancer (LARC).
e15665 Background: Liquid biopsy, particularly the analysis of cfDNA or circulating tumor DNA (ctDNA), has become a tool for diagnosis, monitoring, and tr...
Patterns of second-line treatment in patients with NSCLC and targetable mutations.
e20699 Background: Several studies suggest that up to 30% of patients with non-small cell lung cancer (NSCLC) do not receive second-line systemic therapy....
Integrating cancer support and technology in breast cancer care: Developing a chatbot for underserved populations.
e13545 Background: Breast cancer care often focuses on medical and surgical interventions, with limited attention to the emotional and informational needs...
Continuation of serplulimab-based therapy beyond first progression in advanced gastric/gastroesophageal junction (G/GEJ) cancer: Preliminary results from the SCAFIGC trial.
e16022 Background: Anti-PD-1 in combination with chemotherapy has been confirmed to improve the prognosis of patients with advanced gastric/gastroesophage...
Results of a phase 1 study of vosilasarm (EP0062), a first-in-class oral selective androgen receptor modulator (SARM) in patients with advanced or metastatic AR+/ER+/HER-2- breast cancer.
1057 Background: Vosilasarm (EP0062) is an oral, nonsteroidal, Selective Androgen Receptor Modulator (SARM). Initially developed under the code RAD140, EP...
A prospective non-randomized clinical study to evaluate the efficacy of intraperitoneal PD-1 monoclonal antibody for end-stage liver cancer patients with ascites: Long-term outcomes.
e16203 Background: Patients (pts) with primary hepatocellular carcinoma and significant malignant ascites are typically in the terminal stage of the disea...
Assessment of efficacy of LBL-024, a novel and uniquely designed bispecific antibody against PD-L1 and 4-1BB, combined with etoposide/platinum-based chemotherapy in treatment-naive advanced extrapulmonary neuroendocrine carcinoma (EP-NEC): A multicenter phase Ib/II trial.
2500 Background: The prognosis for patients with EP-NEC is very poor. A recognized 1L treatment for advanced disease is etoposide/platinum-based chemother...